Subscribe to RSS
DOI: 10.1055/s-0030-1255163
© Georg Thieme Verlag KG Stuttgart · New York
Hämatologie 2010
Hematology 2010Publication History
Publication Date:
16 June 2010 (online)
Was ist neu?
-
Hämostaseologie: Neue orale Antikoagulanzien.
-
Myelodysplastisches Syndrom: Azacitidin verlängert das Überleben bei Hochrisiko-Fällen.
-
Chronische lymphatische Leukämie: Erstmals verlängertes Gesamtüberleben belegt.
-
Morbus Waldenström: Der internationale prognostische Score erlaubt eine Abschätzung des klinischen Verlaufs.
-
Follikuläres Lymphom: Bendamustin als gut verträgliche Therapieoption.
-
Aggressives Lymphom: Die Hochdosistherapie mit autologer Stammzelltransplantation zeigt keinen Vorteil in der Erstlinien-Therapie.
-
Multiples Lymphom: Lenalidomid und niedrig-dosiertes Dexamethason in der Primärtherapie.
Literatur
- 1 Connolly S J, Ezekowitz M D, Yusuf S. et al . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 1139-1151
- 2 Eichhorst B, Busch R, Stilgenbauer S. First-line therapy with fludarabine compared with chlorambucil does not result in a major benfit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009; 114 3382-3391
- 3 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10 223-232
- 4 Hallek M, Fingerle-Fowson, Fink A -M. et al . First-line treatment wih Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international roup of investigators and the German CLL study group. Blood. 2009; 114 223 (Abstract 535)
- 5 Hulin C, Facon T, Rodon P. et al . Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. J Clin Oncol. 2009; 27 3664-3670
- 6 Morel P, Duhamel A, Gobbi P. et al . International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009; 119 4163-4170
- 7 Rajkumar S V, Jacobus S, Callander N S. et al . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11 29-37
- 8 Robak T, Dmoszynska A, Solal-Céligny P. et al . Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. JCO. 2010; 28 1756-1765
- 9 Rummel M J, Niederle N, Maschmeyer G. et al . Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL. Blood. 2009; 114 168 (Abstract 405)
- 10 San M iguel JF, Schlag R, Khuageva N K. et al, VISTA Trial Investigators . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359 906-17
- 11 Schmitz N, Nickelsen M, Ziepert M. et al . Aressive chemotherapy (CHOEP-14) and Rituximab or high-dose therapy (MegaCHOEP) and Rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German high-grade non-Hodgkin Lymphoma study group (DSHNHL). Blood. 2009; 114 168 (Abstract 404)
- 12 Schulman S, Kearon C, Kakkar A K. et al . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 2342-2352
Prof. Dr. med. Martin Dreyling
Medizinische Klinik III der Universität München – Großhadern
Marchioninistraße 15
81337 München
Phone: 089/7095-2202
Fax: 089/7095-2201
Email: Martin.Dreyling@med.uni-muenchen.de